Complement Inactivating Agents
"Complement Inactivating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
| Descriptor ID |
D051056
|
| MeSH Number(s) |
D27.505.696.477.656.500
|
| Concept/Terms |
Complement Inactivating Agents- Complement Inactivating Agents
- Agents, Complement Inactivating
- Inactivating Agents, Complement
- Complement Inhibitors
- Inhibitors, Complement
- Complement Inhibiting Agents
- Agents, Complement Inhibiting
- Inhibiting Agents, Complement
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivating Agents".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivating Agents".
This graph shows the total number of publications written about "Complement Inactivating Agents" by people in this website by year, and whether "Complement Inactivating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement Inactivating Agents" by people in Profiles.
-
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):582-592.
-
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1610-1618.e4.
-
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan; 13(1):118-31.
-
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010 Aug 05; 363(6):513-22.